Ferrous Lactate Encyclopedia — Scientific Background

What Is Ferrous Lactate?

Ferrous lactate (CAS 5905-52-2), also known as iron(II) lactate or iron(II) 2-hydroxypropanoate, is the ferrous salt of lactic acid. It is chemically characterized by the molecular formula C₆H₁₀FeO₆ and a molecular weight of 233.99 g/mol (anhydrous) or 288.03 g/mol (trihydrate). The compound occurs as a greenish-white powder or crystalline mass with a weak, characteristic smell and a slightly sweet taste of iron. It is easily soluble in hot water and practically insoluble in ethanol. Ferrous lactate is easily oxidized in light, heat, and air. It contains approximately 19% elemental iron by weight, one of the highest iron contents among organic ferrous salts.

Regulatory Status and Pharmacopoeial Standards

Ferrous lactate holds a well-established regulatory position as both a pharmaceutical and food ingredient:

FDA GRAS Status — Ferrous lactate is affirmed as Generally Recognized As Safe (GRAS) by the FDA under 21 CFR 184.1311 for use as a nutrient supplement and as a color fixative for ripe olives, with no limitation other than current good manufacturing practice. It may also be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act.

FAO/WHO JECFA Monograph — Ferrous lactate is monographed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) with the INS number 585. The assay is not less than 96% on the dried basis. A provisional maximum tolerable daily intake (PMTDI) of 0.8 mg/kg body weight for iron was established at the 35th JECFA (1989).

Food Additive — Ferrous lactate functions as a colouring adjunct and nutrient with the E number E585. It is permitted in food in the European Union, United States, and other regions.

Global Standards — Ferrous lactate conforms to the Food Chemicals Codex (FCC), FAO/WHO, and Chinese national standard GB specifications. The product complies with FCC, FAO/WHO, and GB standards with assay ≥96.0%, loss on drying ≤20%, chloride ≤0.1%, iron(III) ≤0.5%, sulphates ≤0.1%, pH 5.0–6.0, lead ≤1 mg/kg, arsenic ≤3 mg/kg, and stereochemical purity (L/(L+D) × 100) ≥97.0%.

Physiological Functions of Iron

Iron is an essential trace mineral required for numerous physiological processes:

• Hemoglobin Synthesis — Iron is the central atom in the heme group of hemoglobin, enabling oxygen transport from the lungs to tissues

• Oxygen Transport — Iron-containing myoglobin facilitates oxygen storage and transport in muscle tissue

• Electron Transfer — Iron-sulfur clusters and heme groups participate in mitochondrial electron transport chain reactions

• Enzymatic Reactions — Iron is a cofactor for numerous enzymes involved in DNA synthesis, neurotransmitter production, and immune function

• Energy Metabolism — Iron-containing cytochromes are essential for ATP production

Mechanisms of Action and Absorption

Conventional Iron Absorption Pathway

Iron absorption from ferrous lactate follows the normal physiological pathway for non-heme iron. Ferrous iron (Fe²⁺) is absorbed primarily in the duodenum and proximal jejunum through the divalent metal transporter 1 (DMT1). Once inside the enterocyte, iron is either stored as ferritin or transported across the basolateral membrane by ferroportin into the bloodstream, where it binds to transferrin for distribution to tissues. The lactate anion provides greater stability to iron by preventing its decomposition inside the intestinal tube, causing much less gastric irritation than other commonly used inorganic ferrous salts, such as ferrous sulfate.

liposomal Absorption Pathway

Liposomal encapsulation provides a fundamentally different absorption mechanism. The liposomal phospholipid bilayer is similar to cell membranes in the human body, which makes them progressively biocompatible. liposomes protect iron from premature interaction with gastric contents and dietary inhibitors, and facilitate efficient cellular delivery via lipid-mediated pathways. The liposomal delivery system bypasses the regulated DMT1 absorption pathway and provides an alternative route of cellular entry. Liposomal iron offers improved gastrointestinal absorption and bioavailability compared to conventional ferrous salts, with the free iron not chemically interacting with the gastrointestinal membrane. Multiple studies have demonstrated that liposomal iron achieves bioavailability comparable to or exceeding that of ferrous sulfate despite containing lower elemental iron doses, and liposomal iron is 4 times better absorbed compared to conventional iron.

The Bioavailability Challenge

Despite iron's essential physiological functions, conventional oral iron presents absorption limitations. Iron absorption relies on tightly regulated intestinal transport systems, and increasing the administered dose does not proportionally enhance absorption efficiency. Additionally, iron can bind with dietary inhibitors such as phytates and polyphenols, which reduce absorption.

A clinical trial in Thai women consuming iron-fortified fish sauce demonstrated that fractional iron absorption was 8.7% for ferrous lactate compared to 13.0% for ferrous sulfate (P = 0.003), indicating that iron absorption was 50–100% higher from ferrous sulfate than from ferrous lactate in that food matrix. However, liposomal encapsulation addresses these limitations through a phospholipid bilayer that protects iron from gastric degradation and dietary inhibitors, and enhances intestinal absorption through lipid-mediated pathways. Liposomal iron offers improved gastrointestinal absorption and bioavailability compared to conventional ferrous salts.

Liposomal ferrous lactate

Liposomal encapsulation of ferrous lactate provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the iron-lactate complex, forming a protective shell that enhances absorption and reduces gastrointestinal irritation. This delivery system:

• Protects ferrous iron from oxidation in light, heat, and air

• Enhances intestinal absorption through lipid-mediated pathways

• Provides targeted delivery to iron-requiring tissues

• Reduces gastrointestinal side effects by minimizing direct mucosal contact

• Bypasses the regulated DMT1 absorption pathway

A US patent (US5534268) discloses liposomes comprising an iron(II) source selected from the group consisting of ferrous sulfate, ferrous lactate, and ferrous citrate. The iron source is stabilized in aqueous solutions of reducing agents, such as ascorbic acid and soluble ascorbates, which inhibit oxidation of iron(II) to iron(III) and is microencapsulated. The liposomes make it possible to increase the level of bioavailable iron in ingestible substrates.

Clinical Evidence

Iron Absorption from Fortified Fish Sauce

A randomized crossover clinical trial in 10 adult women measured iron absorption from intrinsically labeled ferrous sulfate, ferric ammonium citrate, or ferrous lactate added to Thai fish sauce. Fractional iron absorption (geometric mean; −1s.d., +1s.d.) was 8.7(3.6; 21.4)% for ferrous lactate compared to 13.0(5.4; 31.4)% from ferrous sulfate, P = 0.003. The study concluded that iron absorption was 50–100% higher from ferrous sulfate fortified fish sauce than from fish sauce fortified with ferric ammonium citrate or ferrous lactate.

Liposomal Iron Bioavailability

Multiple studies have demonstrated that liposomal iron achieves bioavailability comparable to or exceeding that of ferrous sulfate despite containing lower elemental iron doses. The liposomal formulation exhibits enhanced palatability and higher bioavailability with reduced gastrointestinal side effects. The dropout rate was approximately 21.6% (437 of 558 completed), which is favorable compared to typical dropout rates of 30–50% with ferrous sulfate. Liposomal iron is 4 times better absorbed compared to conventional iron, with the free iron not chemically interacting with the gastrointestinal membrane.

Liposomal Iron in Clinical Trials

A systematic review and meta-analysis of randomized controlled trials has evaluated the safety and efficacy of liposomal iron in children with iron deficiency anemia compared to conventional iron preparations. The review included studies such as a randomized controlled trial comparing liposomal iron with ferrous sulfate drops in infants with iron deficiency anemia, which demonstrated that both supplements were efficacious, with liposomal iron offering improved gastrointestinal tolerability.

Safety and Regulatory

Ferrous lactate is generally well tolerated, with fewer gastrointestinal side effects compared to some other iron compounds. The most common side effects are gastrointestinal, including nausea, abdominal pain, diarrhea, and constipation. Liposomal encapsulation helps reduce these side effects through improved absorption and reduced gastrointestinal mucosal contact.

Iron status should be monitored through hemoglobin, ferritin, and transferrin saturation to guide dosing, as even well-tolerated forms should not be supplemented without confirmed deficiency due to the risks of iron overload. The Tolerable Upper Intake Level (UL) for iron is 45 mg per day for adults.

Ferrous lactate is widely commercialized as a dietary supplement ingredient, pharmaceutical agent, and food additive. It is Generally Recognized As Safe (GRAS) by the FDA under 21 CFR 184.1311 and is monographed by the FAO/WHO JECFA (INS No. 585) and Food Chemicals Codex (FCC). Testing protocols must adhere to international standards including USP, European Pharmacopoeia, FAO/WHO JECFA, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

69$/KG